Incyte (INCY) News Today $70.45 -0.60 (-0.84%) (As of 11/21/2024 ET) Add Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Incyte's (INCY) "Neutral" Rating Reaffirmed at Cantor FitzgeraldNovember 21 at 5:03 AM | americanbankingnews.comIncyte trading halted, volatility trading pauseNovember 20 at 9:58 AM | markets.businessinsider.comIncyte’s Strategic Growth Potential and Rich Pipeline Underpin Buy Rating at $86 TargetNovember 20 at 9:58 AM | markets.businessinsider.comConnor Clark & Lunn Investment Management Ltd. Lowers Position in Incyte Co. (NASDAQ:INCY)Connor Clark & Lunn Investment Management Ltd. lowered its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 48.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 582,107 shares of the biopharmaceutical company's sNovember 20 at 8:03 AM | marketbeat.comIncyte Faces Challenges but Remains Focused on Strategic GrowthNovember 19 at 7:03 PM | gurufocus.comIncyte trading resumesNovember 19 at 3:09 PM | tipranks.comIncyte price target lowered to $86 from $90 at BofANovember 19 at 2:56 PM | markets.businessinsider.comIncyte Faces Pipeline Setbacks and Growth Challenges, Justifying Sell RatingNovember 19 at 2:56 PM | markets.businessinsider.comThese Stocks Are Moving the Most Today: Super Micro, Walmart, Nvidia, Lowe’s, Symbotic, XPeng, Incyte, and MoreNovember 19 at 2:56 PM | msn.comIncyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock.November 19 at 2:56 PM | msn.comIncyte (NASDAQ:INCY) Shares Gap Down - Here's WhyIncyte (NASDAQ:INCY) Shares Gap Down - Here's WhyNovember 19 at 1:34 PM | marketbeat.comIncyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags ChallengesNovember 19 at 1:10 PM | benzinga.comIncyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other StudyNovember 19 at 12:51 PM | investopedia.comIncyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock.November 19 at 12:21 PM | barrons.comIncyte (NASDAQ:INCY) Given Neutral Rating at Cantor FitzgeraldCantor Fitzgerald reissued a "neutral" rating on shares of Incyte in a research report on Tuesday.November 19 at 9:43 AM | marketbeat.comIncyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.November 19 at 9:23 AM | investors.comIncyte Q3 Earnings TranscriptNovember 19 at 7:02 AM | marketbeat.comIncyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 ProgramsNovember 18 at 5:00 PM | businesswire.comIncyte to lease former Wanamaker building near WilmingtonNovember 17, 2024 | warriorswire.usatoday.comSeizert Capital Partners LLC Buys 10,438 Shares of Incyte Co. (NASDAQ:INCY)Seizert Capital Partners LLC lifted its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 12.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 94,342 shares of the biopharmaceutNovember 17, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Sells 49,495 Shares of Incyte Co. (NASDAQ:INCY)Sumitomo Mitsui Trust Group Inc. reduced its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 9.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 483,699 shares of the biopharmaceutical company's stock after selling 49,495 shares during the perNovember 17, 2024 | marketbeat.comHere’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth ProspectsNovember 16, 2024 | msn.comIncyte Co. (NASDAQ:INCY) Shares Acquired by Mizuho Securities USA LLCMizuho Securities USA LLC increased its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 13,814.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,000,100 shares of the biopharmaceutical company's stock after acquirNovember 16, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. reduced its position in Incyte Co. (NASDAQ:INCY - Free Report) by 10.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 220,750 shares of the biopharmaceutiNovember 16, 2024 | marketbeat.comIncyte price target raised to $80 from $72 at RBC CapitalNovember 15, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For IncyteNovember 14, 2024 | benzinga.comKBC Group NV Reduces Position in Incyte Co. (NASDAQ:INCY)KBC Group NV trimmed its position in Incyte Co. (NASDAQ:INCY - Free Report) by 32.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,161,053 shares of the biopharmaceutical company's stock after sellNovember 14, 2024 | marketbeat.comState of New Jersey Common Pension Fund D Sells 9,769 Shares of Incyte Co. (NASDAQ:INCY)State of New Jersey Common Pension Fund D lowered its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 13.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,559 shares of the biopharmaceutNovember 13, 2024 | marketbeat.comLos Angeles Capital Management LLC Lowers Stock Holdings in Incyte Co. (NASDAQ:INCY)Los Angeles Capital Management LLC trimmed its position in Incyte Co. (NASDAQ:INCY - Free Report) by 43.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 209,795 shares of the biophNovember 12, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Sold by Amalgamated BankAmalgamated Bank lessened its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 16.9% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 31,585 shares of the biopharmaceutical company's stock after selling 6,433 shares during the quarter. Amalgamated Bank's holdinNovember 12, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) EVP Sells $293,222.40 in StockNovember 9, 2024 | insidertrades.comIncyte Co. (NASDAQ:INCY) Shares Sold by Applied Finance Capital Management LLCApplied Finance Capital Management LLC decreased its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 5.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 471,687 shares of the biopharmaceutical company's sNovember 9, 2024 | marketbeat.comBarry P. Flannelly Sells 3,680 Shares of Incyte Co. (NASDAQ:INCY) StockIncyte Co. (NASDAQ:INCY - Get Free Report) EVP Barry P. Flannelly sold 3,680 shares of the firm's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $79.68, for a total value of $293,222.40. Following the completion of the sale, the executive vice president now directly owns 58,042 shares in the company, valued at $4,624,786.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.November 8, 2024 | marketbeat.comARK Investment Management LLC Sells 187,127 Shares of Incyte Co. (NASDAQ:INCY)ARK Investment Management LLC lessened its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 46.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 211,536 shares of the biopharmaceutical company's stock after selling 187,127November 8, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Holdings Lowered by Van ECK Associates CorpVan ECK Associates Corp cut its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 16.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 134,881 shares of the biopharmaceutical company's stock afteNovember 7, 2024 | marketbeat.comGreenwood Capital Associates LLC Buys Shares of 6,546 Incyte Co. (NASDAQ:INCY)Greenwood Capital Associates LLC bought a new stake in Incyte Co. (NASDAQ:INCY - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 6,546 shares of the biopharmaceutical company's stock, valued at approximately $433,November 6, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Purchases 70,596 Shares of Incyte Co. (NASDAQ:INCY)Robeco Institutional Asset Management B.V. grew its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 5.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,265,966 shares of the biopharmaceutical company's stock aftNovember 5, 2024 | marketbeat.comIncyte (NASDAQ:INCY) Sets New 12-Month High - Should You Buy?Incyte (NASDAQ:INCY) Hits New 1-Year High - Here's What HappenedNovember 4, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Stock Position Lowered by New York State Teachers Retirement SystemNew York State Teachers Retirement System lessened its position in Incyte Co. (NASDAQ:INCY - Free Report) by 18.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 173,895 shares of the biopharmaceutical company's stock after selNovember 3, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Stock Holdings Trimmed by State of Alaska Department of RevenueState of Alaska Department of Revenue lessened its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 36.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,059 shares of the biopharmaceutiNovember 2, 2024 | marketbeat.comSell Rating Assigned to Incyte: Concerns Over Jakafi’s Exclusivity Loss and Strategic ChallengesNovember 2, 2024 | markets.businessinsider.comIncyte Corporation (NASDAQ:INCY) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | msn.comIncyte (NASDAQ:INCY) Announces Quarterly Earnings ResultsIncyte (NASDAQ:INCY - Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing analysts' consensus estimates of $1.19 by ($0.12). Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the business posted $0.91 EPS. The company's revenue for the quarter was up 23.8% compared to the same quarter last year.November 1, 2024 | marketbeat.comIncyte’s Strong Financial Performance and Pipeline Potential Justify Buy Rating and Increased Price TargetNovember 1, 2024 | markets.businessinsider.comIncyte Shares Hit 52-Week High After 3Q Revenue Beat, Higher Jakafi GuidanceOctober 31, 2024 | marketwatch.comIncyte price target raised to $82 from $81 at OppenheimerOctober 31, 2024 | markets.businessinsider.comIncyte price target raised to $72 from $67 at RBC CapitalOctober 31, 2024 | markets.businessinsider.comIncyte's Jakafi Demand Is Strong, Analyst Upgrades StockOctober 31, 2024 | finance.yahoo.comIncyte: Q3 Earnings Ramping Up Growth To Jump The Patent CliffOctober 31, 2024 | seekingalpha.comIntegrated Advisors Network LLC Invests $967,000 in Incyte Co. (NASDAQ:INCY)Integrated Advisors Network LLC purchased a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 14,631 shares of the biopharmaceutical company's stOctober 31, 2024 | marketbeat.com Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] INCY Media Mentions By Week INCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INCY News Sentiment▼0.430.47▲Average Medical News Sentiment INCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INCY Articles This Week▼2710▲INCY Articles Average Week Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Medpace News Today Charles River Laboratories International News Today ICON Public News Today National Research News Today Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today Neurocrine Biosciences News Today BioMarin Pharmaceutical News Today Exelixis News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INCY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
